Please read the general information carefully.
Vaccination against SARS-CoV-2 is essential for the whole population, including patients with hidradenitis suppurativa/acne inversa. It is, however, up to the patient if he/she wants to get vaccinated, as it is the personal choice for any other individual.
There is insufficient evidence to understand how COVID-19 likely impacts hidradenitis suppurativa/acne inversa patients undergoing systemic treatment. Patients treated using tumor necrosis factor-alpha blockers, including adalimumab, infliximab, and etanercept, may be exposed to a slightly increased risk of developing upper respiratory tract infections, especially with infliximab.
As the currently available mRNA vaccines are not live vaccines, they should pose no risk to patients with hidradenitis suppurativa/acne inversa, nor to those undergoing immunosuppressive treatment.
Considering the immunosuppressants’ effects on vaccination efficacy, immunosuppression should be as low as possible at the time of vaccination. However, in an effort to potentially enhance the vaccination efficacy, the actual immunosuppressive therapy should not be stopped if it is deemed essential for a severely affected patient.
It is up to the patient if he/she wants to get vaccinated, as it is the free choice for any other individual.
For detailed advice, do not hesitate to contact the specialist who ensures your medical follow-up by means of email, fax, or telephone.